



LEGAL
Wilmington, Delaware 19898

Contains No CBI

8892401751-1
8E4Q-92-12347

ISS2 OCT 27 PM 2:37

OTS 03:0 21

(A)

(1)

No CBI

**Certified Mail
Return Receipt Requested**

October 15, 1992

Document Processing Center (TS-790)
Office of Pollution Prevention and Toxics
Environmental Protection Agency
401 M Street., S.W.
Washington, D.C. 20460
Attn: Section 8(e) Coordinator (CAP Agreement)

Dear Coordinator:

8ECAP-0025

On behalf of the Regulatee and pursuant to Unit II B.1.b. and Unit II C of the 6/28/91 CAP Agreement, E.I. Du Pont de Nemours and Co. hereby submits (*in triplicate*) the attached studies. Submission of this information is voluntary and is occasioned by unilateral changes in EPA's standard as to what EPA now considers as reportable information. Regulatee's submission of information is made solely in response to the new EPA §8(e) reporting standards and is not an admission: (1) of TSCA violation or liability; (2) that Regulatee's activities with the study compounds reasonably support a conclusion of substantial health or environmental risk or (3) that the studies themselves reasonably support a conclusion of substantial health or environmental risk.

The "Reporting Guide" creates new TSCA 8(e) reporting criteria which were not previously announced by EPA in its 1978 Statement of Interpretation and Enforcement Policy, 43 Fed Reg 11110 (March 16, 1978). The "Reporting Guide" states criteria which expands upon and conflicts with the 1978 Statement of Interpretation. Absent amendment of the Statement of Interpretation, the informal issuance of the "Reporting Guide" raises significant due processes issues and clouds the appropriate reporting standard by which regulated persons can assure TSCA Section 8(e) compliance.

For Regulatee,

Mark H. Christman
Counsel
Legal D-7158
1007 Market Street
Wilmington, DE 19898
(302) 774-6443

mm
4/26/95

ATTACHMENT 1

Submission of information is made under the 6/28/91 CAP Agreement, Unit II. This submission is made voluntarily and is occasioned by recent changes in EPA's TSCA §8(e) reporting standard; such changes made, for the first time in 1991 and 1992 without prior notice and in violation of Regulatee's constitutional due process rights. Regulatee's submission of information under this changed standard is not a waiver of its due process rights; an admission of TSCA violation or liability, or an admission that Regulatee's activities with the study compounds reasonably support a conclusion of substantial risk to health or to the environment. Regulatee has historically relied in good faith upon the 1978 Statement of Interpretation and Enforcement Policy criteria for determining whether study information is reportable under TSCA §8(e), 43 Fed Reg 11110 (March 16, 1978). EPA has not, to date, amended this Statement of Interpretation.

After CAP registration, EPA provided the Regulatee the June 1, 1991 "TSCA Section 8(e) Reporting Guide". This "Guide" has been further amended by EPA, EPA letter, April 10, 1992. EPA has not indicated that the "Reporting Guide" or the April 1992 amendment supersedes the 1978 Statement of Interpretation. The "Reporting Guide" and April 1992 amendment substantively lowers the Statement of Interpretation's TSCA §8(e) reporting standard². This is particularly troublesome as the "Reporting Guide" states criteria, applied retroactively, which expands upon and conflicts with the Statement of Interpretation.³ Absent amendment of the Statement of Interpretation, the informal issuance of the "Reporting Guide" and the April 1992 amendment clouds the appropriate standard by which regulated persons must assess information for purposes of TSCA §8(e).

²In sharp contrast to the Agency's 1977 and 1978 actions to soliciting public comment on the proposed and final §8(e) Policy, EPA has unilaterally pronounced §8(e) substantive reporting criteria in the 1991 Section 8(e) Guide without public notice and comment. See 42 Fed Reg 45362 (9/9/77), "Notification of Substantial Risk under Section 8(e): Proposed Guidance".

³A comparison of the 1978 Statement of Interpretation and the 1992 "Reporting Guide" is appended.

Throughout the CAP, EPA has mischaracterized the 1991 guidance as reflecting "longstanding" EPA policy concerning the standards by which toxicity information should be reviewed for purposes of §8(e) compliance. Regulatee recognizes that experience with the 1978 Statement of Interpretation may cause a review of its criteria. Regulatee supports and has no objection to the Agency's amending reporting criteria *provided that* such amendment is not applied to the regulated community in an unfair way. However, with the unilateral announcement of the CAP under the auspices of an OCM enforcement proceeding, EPA has wrought a terrific unfairness since much of the criteria EPA has espoused in the June 1991 Reporting Guide and in the Agency's April 2, 1992 amendment is new criteria which does not exist in the 1978 Statement of Interpretation and Enforcement Policy.

The following examples of new criteria contained in the "Reporting Guide" that is not contained in the Statement of Interpretation follow:

- o even though EPA expressly disclaims each "status report" as being preliminary evaluations that should not be regarded as final EPA policy or intent⁴, the "Reporting Guide" gives the "status reports" great weight as "sound and adequate basis" from which to determine mandatory reporting obligations. ("Guide" at page 20).
- o the "Reporting Guide" contains a matrix that establishes new numerical reporting "cutoff" concentrations for acute lethality information ("Guide" at p. 31). Neither this matrix nor the cutoff values therein are contained in the Statement of Interpretation. The regulated community was not made aware of these cutoff values prior to issuance of the "Reporting Guide" in June, 1991.
- o the "Reporting Guide" states new specific definitional criteria with which the Agency, for the first time, defines as 'distinguishable neurotoxicological effects'; such criteria/guidance not expressed in the 1978 Statement of Interpretation.⁵;
- o the "Reporting Guide" provides new review/ reporting criteria for irritation and sensitization studies; such criteria not previously found in the 1978 Statement of Interpretation/Enforcement Policy.
- o the "Reporting Guide" publicizes certain EPA Q/A criteria issued to the Monsanto Co. in 1989 which are not in the Statement of Interpretation; have never been published in the Federal Register or distributed by the EPA to the Regulatee. Such Q/A establishes new reporting criteria not previously found in the 1978 Statement of Interpretation/Enforcement Policy.

⁴The 'status reports' address the significance, if any, of particular information reported to the Agency, rather than stating EPA's interpretation of §8(e) reporting criteria. In the infrequent instances in which the status reports contain discussion of reportability, the analysis is invariably quite limited, without substantial supporting scientific or legal rationale.

⁵ See, e.g., 10/2/91 letter from Du Pont to EPA regarding the definition of 'serious and prolonged effects' as this term may relate to transient anesthetic effects observed at lethal levels; 10/1/91 letter from the American Petroleum Institute to EPA regarding clarification of the Reporting Guide criteria.

In discharging its responsibilities, an administrative agency must give the regulated community fair and adequate warning to as what constitutes noncompliance for which penalties may be assessed.

Among the myriad applications of the due process clause is the fundamental principle that statutes and regulations which purport to govern conduct must give an adequate warning of what they command or forbid.... Even a regulation which governs purely economic or commercial activities, if its violation can engender penalties, must be so framed as to provide a constitutionally adequate warning to those whose activities are governed.

Diebold, Inc. v. Marshall, 585 F.2d 1327, 1335-36 (D.C. Cir. 1978). See also, Rollins Environmental Services (NJ) Inc. v. U.S. Environmental Protection Agency, 937 F. 2d 649 (D.C. Cir. 1991).

While neither the are rules, This principle has been applied to hold that agency 'clarification', such as the Statement of Interpretation, the "Reporting Guide" nor the April 1992 amendments will not applied retroactively.

...a federal court will not retroactively apply an unforeseeable interpretation of an administrative regulation to the detriment of a regulated party on the theory that the post hoc interpretation asserted by the Agency is generally consistent with the policies underlying the Agency's regulatory program, when the semantic meaning of the regulations, as previously drafted and construed by the appropriate agency, does not support the interpretation which that agency urges upon the court.

Standard Oil Co. v. Federal Energy Administration, 453 F. Supp. 203, 240 (N.D. Ohio 1978), aff'd sub nom. Standard Oil Co. v. Department of Energy, 596 F.2d 1029 (Em. App. 1978):

The 1978 Statement of Interpretation does not provide adequate notice of, and indeed conflicts with, the Agency's current position at §8(e) requires reporting of all 'positive' toxicological findings without regard to an assessment of their relevance to human health. In accordance with the statute, EPA's 1978 Statement of Interpretation requires the regulated community to use scientific judgment to evaluate the significance of toxicological findings and to determining whether they reasonably support a conclusion of a substantial risk. Part V of the Statement of Interpretation urges persons to consider "the fact or probability" of an effect's occurrence. Similarly, the 1978 Statement of Interpretation stresses that an animal study is reportable only when "it contains reliable evidence ascribing the effect to the chemical." 43 Fed Reg. at 11112. Moreover, EPA's Statement of Interpretation defines the substantiality of risk as a function of both the seriousness of the effect and the probability of its occurrence. 43 Fed Reg 11110 (1978). Earlier Agency interpretation also emphasized the "substantial" nature of a §8(e) determination. See 42 Fed Reg 45362, 45363

(1977). [Section 8(e) findings require "extraordinary exposure to a chemical substance...which critically imperil human health or the environment"]].

The recently issued "Reporting Guide" and April 1992 Amendment guidance requires reporting beyond and inconsistent with that required by the Statement of Interpretation. Given the statute and the Statement of Interpretation's explicit focus on substantial human or environmental risk, whether a substance poses a "substantial risk" of injury requires the application of scientific judgment to the available data on a case-by-case basis.

If an overall weight-of-evidence analysis indicates that this classification is unwarranted, reporting should be unnecessary under §8(e) because the available data will not "reasonably support the conclusion" that the chemical presents a substantial risk of serious adverse consequences to human health.

Neither the legislative history of §8(e) nor the plain meaning of the statute support EPA's recent lowering of the reporting threshold that TSCA §8(e) was intended to be a sweeping information gathering mechanism. In introducing the new version of the toxic substances legislation, Representative Eckhart included for the record discussion of the specific changes from the version of H. R. 10318 reported by the Consumer Protection and Finance Subcommittee in December 1975. One of these changes was to modify the standard for reporting under §8(e). The standard in the House version was changed from "causes or contributes to an unreasonable risk" to "causes or significantly contributes to a substantial risk". This particular change was one of several made in TSCA §8 to avoid placing an undue burden on the regulated community. The final changes to focus the scope of Section 8(e) were made in the version reported by the Conference Committee.

The word "substantial" means "considerable in importance, value, degree, amount or extent". Therefore, as generally understood, a "substantial risk" is one which will affect a considerable number of people or portion of the environment, will cause serious injury and is based on reasonably sound scientific analysis or data. Support for the interpretation can be found in a similar provision in the Consumer Product Safety Act. Section 15 of the CPSA defines a "substantial product hazard" to be:

"a product defect which because of the pattern of defect, the number of defective products distributed in commerce, the severity of the risk, or otherwise, creates a substantial risk of injury to the public."

Similarly, EPA has interpreted the word 'substantial' as a quantitative measurement. Thus, a 'substantial risk' is a risk that can be quantified, See, 56 Fed Reg 32292, 32297 (7/15/91). Finally, since information pertinent to the exposure of humans or the environment to chemical substances or mixtures may be obtained by EPA through Sections 8(a) and 8(d) regardless of the degree of potential risk, §8(e) has specialized function. Consequently, information subject to §8(e) reporting should be of a type which would lead a reasonable man to conclude that some type action was required immediately to prevent injury to health or the environment.

Attachment

Comparison:

Reporting triggers found in the 1978 "Statement of Interpretation/ Enforcement Policy", 43 Fed Reg 11110 (3/16/78) and the June 1991 *Section 8(e) Guide*.

TEST TYPE <u> </u>	1978 POLICY <u>CRITERIA EXIST?</u>	New 1991 GUIDE <u>CRITERIA EXIST?</u>
ACUTE LETHALITY		
Oral	N}	Y}
Dermal	N}	Y}
Inhalation (Vapors)	} ⁶	} ⁷
aerosol	N}	Y}
dusts/ particles	N}	Y}
SKIN IRRITATION	N	Y ⁸
SKIN SENSITIZATION (ANIMALS)	N	Y ⁹
EYE IRRITATION	N	Y ¹⁰
SUBCHRONIC (ORAL/DERMAL/INHALATION)	N	Y ¹¹
REPRODUCTION STUDY	N	Y ¹²
DEVELOPMENTAL TOX	Y ¹³	Y ¹⁴

⁶43 Fed Reg at 11114, comment 14:

"This policy statements directs the reporting of specific effects when unknown to the Administrator. Many routine tests are based on a knowledge of toxicity associated with a chemical. unknown effects occurring during such a range test may have to be reported if they are those of concern to the Agency and if the information meets the criteria set forth in Parts V and VII."

⁷Guide at pp.22, 29-31.

⁸Guide at pp-34-36.

⁹Guide at pp-34-36.

¹⁰Guide at pp-34-36.

¹¹Guide at pp-22; 36-37.

¹²Guide at pp-22

¹³43 Fed Reg at 11112

"Birth Defects" listed.

¹⁴Guide at pp-22

NEUROTOXICITY	N	Y ¹⁵
CARCINOGENICITY	Y ¹⁶	Y ¹⁷
MUTAGENICITY		
<i>In Vitro</i>	Y ¹⁸	Y ¹⁹
<i>In Vivo</i>	Y}	Y}
ENVIRONMENTAL		
Bioaccumulation	Y}	N
Bioconcentration	Y ²⁰	N
Oct/water Part. Coeff.	Y}	N
Acute Fish	N	N
Acute Daphnia	N	N
Subchronic Fish	N	N
Subchronic Daphnia	N	N
Chronic Fish	N	N
AVIAN		
Acute	N	N
Reproductive	N	N
Reproductive	N	N

¹⁵Guide at pp-23; 33-34.

¹⁶43 Fed Reg at 11112

"Cancer" listed

¹⁷Guide at pp-21.

¹⁸43 Fed Reg at 11112; 11115 at Comment 15

"Mutagenicity" listed/ *in vivo* vs *in vitro* discussed; discussion of "Ames test".

¹⁹Guide at pp-23.

²⁰43 Fed Reg at 11112; 11115 at Comment 16.

CAS # See below for CAS No.s

Chem: 1,1,1-trichloropentafluoropropane (Freon 215cb);
1,1,3-trichloropentafluoropropane (Freon 215ca);
heptafluoroisopropylethyl ether; 1,2-dichlorohexa-
fluorocyclobutane (fluorocarbon C-316); 2,2-bis(tri-
fluoromethyl)-1,3-dioxolane (Dioxolane 456); 2,2-
bis(trifluoromethyl)tetrafluoro-1,3-dioxolane (Dioxo-
lane 41-10); 2,2,-bis(trifluoromethyl)-4-chlorotrifluoro-
1,3-dioxolane (Dioxolane 419); 2,2-bis(trifluoromethyl)-
4,5-dichloro-4,5-difluoro-1,3-dioxolane (Dioxolane
418); bis(pentafluoroethyl) sulfone

Title: Cardiac sensitization screening studies

Date: ?/8/68

Summary of Effects: Sensitizes mammalian heart to adrenalin

Chemical CAS No.

1,1,1-trichloropentafluoropropane	4259-43-2
1,1,3-trichloropentafluoropropane	1652-81-9
heptafluoroisopropylethyl ether	22137-14-0
1,2-dichlorohexa-fluorocyclobutane	356-18-3
2,2-bis(tri-fluoromethyl)-1,3-dioxolane	1765-26-0
2,2-bis(trifluoromethyl)tetrafluoro-1,3- dioxolane	64499-64-5
2,2,-bis(trifluoromethyl)-4-chlorotrifluoro- 1,3-dioxolane	135014-05-0
2,2-bis(trifluoromethyl)-4,5-dichloro-4,5- difluoro-1,3-dioxolane	64499-83-8
bis(pentafluoroethyl) sulfone	14930-22-4

BEST COPY AVAILABLE

Copies to: C. W. Maynard
R. Moore R. J. Plunkett(6)
R. M. Glover, Jr.(6) R. D. Richardson
D. E. Kvalnes C. E. Wilson, Jr.

E. I. du Pont de Nemours and Company
Haskell Laboratory for Toxicology and Industrial Medicine
HASKELL LABORATORY REPORT NO. 93-68

MR NO. 1074-3

Materials Tested:

Haskell Nos.:

- | | |
|--|----------------|
| 1) 1,1,1-trichloropentafluoropropane (Freon [®] 215cb) | 5328 |
| 2) 1,1,3-trichloropentafluoropropane (Freon [®] 215ca) | 5410 |
| 3) heptafluoroisopropylethyl ether | 5331
5331-2 |
| 4) 1,2-dichlorohexafluorocyclobutane (fluorocarbon C-316) | 5329 |
| 5) 2,2-bis(trifluoromethyl)-1,3-dioxolane (Dioxolane 456) | 5330 |
| 6) 2,2-bis(trifluoromethyl)tetrafluoro-1,3-dioxolane (Dioxolane 41-10) | 5366 |
| 7) 2,2-bis(trifluoromethyl)-4-chlorotrifluoro-1,3-dioxolane (Dioxolane 419) | 5367 |
| 8) 2,2-bis(trifluoromethyl)-4,5-dichloro-4,5-difluoro-1,3-dioxolane (Dioxolane 418) | 5576 |
| 9) bis(pentafluoroethyl) sulfone | 5381
5381-2 |
| 10) Azeotrope of 30% 1,1,2-trichloro-1,2,2-trifluoroethane (Freon [®] 113) and 70% perfluorodimethylcyclobutane (Freon [®] C51-12) by weight | 5426 |
| 11) Mixture of 25% Freon [®] C51-12 and 75% fluorocarbon C-316 by weight | 4806
5451-2 |

Materials Submitted By: Ralph Moore, Freon[®] Products Research Section, Research and Development Division, Organic Chemicals Department, Experimental Station

CARDIAC SENSITIZATION SCREENING STUDIES

Beagle dogs were exposed to each of the test compounds in the concentration (nominal) and for the duration shown in Table 1. The dogs received a control injection of adrenalin (0.006 mg/kg) intravenously prior to the exposure and a challenge injection (same dosage) after breathing the test material for the stated duration; except that in the case of the azeotrope (H-5426), the challenge injection was given at the beginning of the 30-second exposure period.

The results are given in Table 1 in the column headed "Number of Marked Responses." A marked response indicates the development, after the challenge injection of adrenalin, of a cardiac arrhythmia which was considered to pose a serious threat to life.

It is concluded on the basis of these preliminary studies that Freon® 215cb, Freon® 215ca, fluorocarbon C-316, the azeotrope of 30% Freon® 113 and 70% Freon® C51-12 and the mixture of 25% Freon® C51-12 and 75% fluorocarbon C-316 are capable of sensitizing the mammalian heart to adrenalin.

Report by: Charles F. Reinhardt
Charles F. Reinhardt, M.D.

Approved by: John A. Zapp Jr.
John A. Zapp, Jr., Director

R/dyb
y 8, 1968

Table 1

Test Compound	Nominal Conc. (% V/V)	Duration of Exposure (min.)	Number of Dog Exposures	Number of Marked Responses	Per Cent Marked Responses	Comments
Freon [®] 215cb	1.0	5	6	1	16.7	• Higher concentrations not tolerated.
	2.5	5	6	6	100.0	
Freon [®] 215ca	1.0	5	7	2	28.6	• These were borderline marked responses. Not well tolerated.
	2.5	5	7	2	28.6	
heptafluoroisopropylethyl ether	1.0	5	6	0	0.0	•
	2.5	5	6	0	0.0	
	5.0	5	6	0	0.0	
Fluorocarbon C-316	1.0	5	6	0	0.0	•
	1.5	5	6	3	50.0	
	2.5	5	2	2	100.0	
	5.0	5	2	2	100.0	
Dioxolane 456	0.25	5	6	0	0.0	• Higher concentrations not tolerated.
	0.5	5	6	0	0.0	
Dioxolane 41-10	1.0	5	5	0	0.0	•
Dioxolane 419	1.0	5	6	0	0.0	•
Dioxolane 418	5.0	1	6	0	0.0	•
bis(pentafluoroethyl) sulfone	1.0	5	6	0	0.0	•
	5.0	1	6	0	0.0	
Azeotrope of 30% Freon [®] 113 and 70% Freon [®] 151-12	1.0 (Freon [®] 113)	1/2	12	1	8.3	
Mixture of 25% Freon [®] 151-12 and 75% Fluorocarbon C-316	5.0 (Fluorocarbon C-316)	1	6	4	66.7	

* Previously reported in Haskell Laboratory Report No. 183-67.

CAS # See below for CAS No.s

Chem: 1,1,1-trichloropentafluoropropane (Freon 113cb);
1,1,3-trichloropentafluoropropane (Freon 215ca);
heptafluoroisopropylethyl ether; 1,2-dichlorohexa-
fluorocyclobutane (fluorocarbon C-316); 2,2-bis(tri-
fluoromethyl)-1,3-dioxolane (Dioxolane 456); 2,2-
bis(trifluoromethyl)tetrafluoro-1,3-dioxolane (Dioxo-
lane 41-10); 2,2-bis(trifluoromethyl)-4-chlorotrifluoro-
1,3-dioxolane (Dioxolane 419); 2,2-bis(trifluoromethyl)-
4,5-dichloro-4,5-difluoro-1,3-dioxolane (Dioxolane
418); bis(pentafluoroethyl) sulfone

Title: Cardiac sensitization screening studies

Date: ?/8/68

Summary of Effects: Sensitizes mammalian heart to adrenalin

Chemical CAS No.

Propane, 1,1,1-trichloropentafluoropropane	4259-43-2	→ Freon 215cb
Propane, 1,1,3-trichloropentafluoropropane	1652-81-9	→ Freon 215ca
heptafluoroisopropylethyl ether	22137-14-0	fluorocarbon
Butane, 1,2-dichlorohexa-fluorocyclobutane	356-18-3	→ Fluorocarbon C-316
1,3-dioxolane, 2,2-bis(tri-fluoromethyl)-1,3-dioxolane	1765-26-0	→ Dioxolane 456
1,3-dioxolane, 2,2-bis(trifluoromethyl)tetrafluoro-1,3-dioxolane	64499-5	→ Dioxolane 41-10
1,3-dioxolane, 2,2-bis(trifluoromethyl)-4-chlorotrifluoro-1,3-dioxolane	135014-05-0	→ Dioxolane 419
1,3-dioxolane, 2,2-bis(trifluoromethyl)-4,5-dichloro-4,5-difluoro-1,3-dioxolane	64499-83-8	→ Dioxolane 418
Sulfone, bis(pentafluoroethyl) sulfone	14930-22-4	

Azeotrope → unknown

76-13-1 → Freon 113

unknown → Freon C53-12

unknown → Freon C51-12

Triage of 8(e) Submissions

Date sent to triage: 2/5/96

NON-CAP

CAP

Submission number: 12307A

TSCA Inventory:

Y

N

D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO

AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX

SBTOX

SEN

w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX

CTOX

EPI

RTOX

GTOX

STOX/ONCO

CTOX/ONCO

IMMUNO

CYTO

NEUR

Other (FATE, EXPO, MET, etc.): _____

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

same study as 12376A

For Contractor Use Only			
entire document:	<u>0</u>	1 2	pages <u>1, 1st tab</u>
Notes:			
Contractor reviewer:	<u>LPS</u>	Date:	<u>12/6/95</u>

CECATS/TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA

Submission # SEHQ-1092-12307 SEQ. A

TYPE: INT. SUPP FLWP

SUBMITTER NAME: E. I. DuPont de Nemours and Company

INFORMATION REQUESTED: FLWP DATE:

0301 NO INFO REQUESTED

0302 INFO REQUESTED (TECH)

0303 INFO REQUESTED (VOL ACTIONS)

0304 INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION:

0305 REFER TO CHEMICAL SCREENING

0306 CAP NOTICE

VOLUNTARY ACTIONS

0401 ACTION REQUESTED

0402 STRIKE PLANNING (HUMAN)

0403 INTERVENTION IN WORKING CONDITION

0404 LAMINATIONS (HUMAN)

0405 PROCESSING IN (HUMAN)

0406 APPAUSE DISCONTINUED

0407 PRODUCTION DISCONTINUED

0408 CONFIDENTIAL

SUB. DATE: 10/15/92 OTH DATE: 10/27/92 CERAD DATE: 04/26/95

CHEMICAL NAME

CASE

See Attached

INFORMATION TYPE:

P.F.C.

INFORMATION TYPE:

P.F.C.

INFORMATION TYPE:

P.F.C.

0201 ONCO (HUMAN) 01 02 04
0202 ONCO (ANIMAL) 01 02 04
0203 CELL TRANS (IN VITRO) 01 02 04
0204 MUTA (IN VITRO) 01 02 04
0205 MUTA (IN VIVO) 01 02 04
0206 REPRO/ITERATO (HUMAN) 01 02 04
0207 REPRO/ITERATO (ANIMAL) 01 02 04
0208 NEURO (HUMAN) 01 02 04
0209 NEURO (ANIMAL) 01 02 04
0210 ACUTE TOX. (HUMAN) 01 02 04
0211 CHR. TOX. (HUMAN) 01 02 04
0212 ACUTE TOX. (ANIMAL) 01 02 04
0213 SUB ACUTE TOX (ANIMAL) 01 02 04
0214 SUB CHRONIC TOX (ANIMAL) 01 02 04
0215 CHRONIC TOX (ANIMAL) 01 02 04

0216 EPICLIN 01 02 04
0217 HUMAN EXPOS (PROD CONTAM) 01 02 04
0218 HUMAN EXPOS (ACCIDENTAL) 01 02 04
0219 HUMAN EXPOS (MONITORING) 01 02 04
0220 BIOAQUA TOX 01 02 04
0221 ENV. OCCURENCE/FATE 01 02 04
0222 EMER INCI OF ENV CONTAM 01 02 04
0223 RESPONSE REQUEST DELAY 01 02 04
0224 PROD/COMP/CHM ID 01 02 04
0225 REPORTING RATIONALE 01 02 04
0226 CONFIDENTIAL 01 02 04
0227 ALLERG (HUMAN) 01 02 04
0228 ALLERG (ANIMAL) 01 02 04
0229 METAPHARMACO (ANIMAL) 01 02 04
0230 METAPHARMACO (HUMAN) 01 02 04

0301 IMMUNO (ANIMAL) 01 02 04
0302 IMMUNO (HUMAN) 01 02 04
0303 CHEMPHYS PROP 01 02 04
0304 CLASTO (IN VITRO) 01 02 04
0305 CLASTO (ANIMAL) 01 02 04
0306 CLASTO (HUMAN) 01 02 04
0307 DNA DAMREPAIR 01 02 04
0308 PRODUCE/PROC 01 02 04
0309 MEDS 01 02 04
0310 OTHER 01 02 04

TRACER DATA

NON-CH INVENTORY

ONGOING REVIEW

SPECIES

TOXICOLOGICAL CONCERN

USE

PRODUCTION:

CAS SR

YES

NO

IN TRIMM

YES (DROP/REFER)

NO (CONTINUE)

REFER

DOG

LOW

MED

HIGH

1-1000013

12307A (same as 12376A)

L

Freon 215cb: Cardiac sensitization in dogs is of low concern. Beagle dogs were challenged with epinephrine during 5-minute exposures to 10,000 and 15,000 ppm of the test substance. Cardiac arrhythmia was noted in 1/6 dogs at 10,000 ppm and 6/6 dogs at 15,000 ppm.

L

Freon 215ca: Cardiac sensitization in dogs is of low concern. Beagle dogs were challenged with epinephrine during a 5-minute exposure to 10,000 ppm of the test substance. Cardiac arrhythmia was noted in 2/7 dogs at 10,000 ppm.

L

Heptafluoroisopropylethyl ether: Cardiac sensitization in dogs is of low concern. Beagle dogs were challenged with epinephrine during 5-minute exposures to 10,000, 25,000 and 50,000 ppm of the test substance. Cardiac arrhythmia was not observed in any of the groups.

L

Fluorocarbon C-316: Cardiac sensitization in dogs is of low concern. Beagle dogs were challenged with epinephrine during 5-minute exposures to 10,000, 15,000, 25,000, and 50,000 ppm of the test substance. Cardiac arrhythmia was noted in 0/6 dogs at 10,000 ppm, 3/6 dogs at 15,000 ppm, 2/2 dogs at 25,000 50,000 ppm.

L

Dioxolane 456: Cardiac sensitization in dogs is of low concern. Six beagle dogs were challenged with epinephrine during a 5-minute exposure to 2,500 ppm of the test substance. Cardiac arrhythmia was not observed in any of the animals.

L

Dioxolane 41-10: Cardiac sensitization in dogs is of low concern. Five beagle dogs were challenged with epinephrine during a 5-minute exposure to 10,000 ppm of the test substance. Cardiac arrhythmia was not observed in any of the animals.

L

Dioxolane 419: Cardiac sensitization in dogs is of low concern. Six beagle dogs were challenged with epinephrine during a 5-minute exposure to 10,000 ppm of the test substance. Cardiac arrhythmia was not observed in any of the animals.

L

Dioxolane 418: Cardiac sensitization in dogs is of low concern. Six beagle dogs were challenged with epinephrine during a 1-minute exposure to 50,000 ppm of the test substance. Cardiac arrhythmia was not observed in any of the animals.

L

Bis(pentafluoroethyl)sulfone: Cardiac sensitization in dogs is of low concern. Beagle dogs were challenged with epinephrine during a 5-minute exposure to 10,000 ppm or a 1-minute exposure to 50,000 ppm of the test substance. Cardiac arrhythmia was not observed in any of the groups.

L

Freon 113 and Freon C51-12 mixture: Cardiac sensitization in dogs is of low concern. Beagle dogs were challenged with epinephrine during a 30-second exposure to 10,000 ppm of the test substance. Cardiac arrhythmia was noted in 1/12 dogs at 10,000 ppm.

L

Freon C51-12 and fluorocarbon C-316 mixture: Cardiac sensitization in dogs is of low concern. Beagle dogs were challenged with epinephrine during a 1-minute exposure to 50,000 ppm of the test substance. Cardiac arrhythmia was noted in 4/6 dogs at 50,000 ppm.